New hope for rare lymphomas: daratumumab trial targets Hard-to-Treat cancers
NCT ID NCT05907759
First seen Feb 18, 2026 · Last updated Jun 12, 2026 · Updated 20 times
Summary
This study tests a drug called daratumumab in people with three rare and aggressive blood cancers (primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease) that have not responded to standard therapy. The drug is given as a weekly injection under the skin for 8 weeks, then less often, for up to 2 years. The goal is to see if it can shrink or control the cancer, with follow-up for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, PRIMARY EFFUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.